Multicenter Study to Evaluate the Safety and Efficacy of MK-0518 [raltegravir] in Combination With An Optimized Background Therapy (OBT), Versus OBT Alone, in HIV-Infected Patients With Documented Resistance
Latest Information Update: 06 May 2022
At a glance
- Drugs Raltegravir (Primary)
- Indications HIV infections; HIV-1 infections
- Focus Therapeutic Use
- Sponsors Merck & Co; Merck Sharp & Dohme Corp.
- 01 Apr 2010 96-week results published in the Journal of Acquired Immune Deficiency Syndromes.
- 30 Oct 2009 144-week results of open-label extension presented at the 47th Annual Meeting of the Infectious Diseases Society of America.
- 31 Aug 2009 Inclusion and exclusion criteria amended and additional trial identifier MK0518-005 identified as reported by ClinicalTrials.gov.